State Street’s Gain Therapeutics GANX Stock Holding History

State Street’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Hold	157,537	–	–	﹤0.01%	3699
2026 Q1	$306K	Hold	157,537	–	–	﹤0.01%	3778
2025 Q4	$507K	Buy	157,537 +66,400	+73%	+$177K	﹤0.01%	3672
2025 Q3	$161K	Buy	91,137 +20,000	+28%	+$33.7K	﹤0.01%	3964
2025 Q2	$128K	Hold	71,137	–	–	﹤0.01%	3933
2025 Q1	$136K	Hold	71,137	–	–	﹤0.01%	3903
2024 Q4	$154K	Buy	71,137 +36,700	+107%	+$73.7K	﹤0.01%	3908
2024 Q3	$61.3K	Hold	34,437	–	–	﹤0.01%	4065
2024 Q2	$44.1K	Buy	34,437 +3,600	+12%	+$9.35K	﹤0.01%	4165
2024 Q1	$116K	Buy	+30,837	New	+$128K	﹤0.01%	4003

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street's GANX Position: Q2 2026 in Review

State Street held its Gain Therapeutics (GANX) position steady in Q2 2026 at 157,537 shares worth $320K. The position accounts for ﹤0.01% of the portfolio, ranked #3699.

State Street first reported a position in GANX in Q1 2024 and has held it in 10 quarters since. The position peaked at $507K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

State Street held 157,537 shares of Gain Therapeutics worth $320K as of Q2 2026.
State Street left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3699 holding.
State Street first reported a position in Gain Therapeutics in Q1 2024 and has held it in 10 quarters since.
State Street's Gain Therapeutics position peaked at $507K in Q4 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.